文献速递白血病

儿童淋巴母细胞白血病的减强度治疗:Recife RELLA05 试点研究长期结果

Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study.
PubMed 文献 · Blood · 2020-01-01

该试点研究在巴西资源匮乏地区纳入454例儿童急性淋巴细胞白血病(ALL)患者,用简化流式细胞术识别101例极低危前体B细胞ALL(VLR B-ALL),给予减强度化疗方案RELLA05。中位随访6.6年,5年无事件生存率和总生存率分别为92.0%±3.9%和96.0%±2.8%,5年累积复发风险4.24%±2.0%,耐受性良好。

要点

  • 极低危标准包括年龄≥1且<10岁、白细胞<50×10⁹/L、无髓外白血病及诱导第19天MRD<0.01%。
  • 减强度方案除2剂柔红霉素外,采用低髓毒性药物组合,未用环磷酰胺、全身阿糖胞苷及中枢神经系统放疗。
  • 101例极低危患者中,诱导期无毒性死亡或治疗放弃,中位随访6.6年仅有8例重大不良事件。

核心结论

  • 通过临床表现特征和早期缓解程度筛选的B-ALL患者,可成功采用轻度骨髓抑制性化疗方案治疗。

主要发现

  • 101例VLR B-ALL患者中,诱导期无毒性死亡或治疗放弃。
  • 中位随访6.6年,共8例重大不良事件:6例复发、1例缓解期治疗相关死亡(败血症)、1例继发性髓系白血病。
  • 估计5年无事件生存率为92.0%±3.9%,总生存率为96.0%±2.8%。
  • 5年累积复发风险为4.24%±2.0%。
  • 治疗耐受性良好,中性粒细胞减少持续时间短。

关键数值与推荐

  • VLR标准:年龄≥1且<10岁、白细胞计数<50×10⁹/L、无髓外白血病、诱导缓解第19天微小残留病水平<0.01%。
  • 减强度方案除2剂柔红霉素外,包括皮质激素、长春新碱、L-天冬酰胺酶、甲氨蝶呤和6-巯基嘌呤。
  • 未使用环磷酰胺、全身阿糖胞苷和中枢神经系统放疗。

临床怎么用

  • 在资源匮乏地区,可结合初诊特征和早期MRD反应识别极低危B-ALL儿童,采用低髓毒性方案以降低治疗相关死亡。

局限性

  • 为单中心试点研究,样本量有限,结果需更大规模研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Treatment-related mortality is common among children with acute lymphoblastic leukemia (ALL) treated in poor-resource settings. We applied a simplified flow cytometric assay to identify patients with precursor B-cell ALL (B-ALL) at very low risk (VLR) of relapse and treated them with a reduced-intensity treatment plan (RELLA05). VLR criteria include favorable presenting features (age ≥ 1 and < 10 years), white blood cell count of <50 ×109/L, lack of extramedullary leukemia, and minimal residual disease level of <0.01% on remission induction day 19. Except for 2 doses of daunorubicin, treatment of patients with VLR B-ALL consisted of a combination of agents with relatively low myelotoxicity profiles, including corticosteroids, vincristine, L-asparaginase, methotrexate, and 6-mercaptopurine. Cyclophosphamide, systemic cytarabine, and central nervous system radiotherapy were not used. Of 454 patients with ALL treated at the Instituto de Medicina Integral Professor Fernando Figueira in Recife, Brazil, between December 2005 and June 2015, 101 were classified as having VLR B-ALL. There were no cases of death resulting from toxicity or treatment abandonment during remission induction. At a median follow-up of 6.6 years, there were 8 major adverse events: 6 relapses, 1 treatment-related death (from septicemia) during remission, and 1 secondary myeloid leukemia. The estimated 5-year event-free and overall survival rates were 92.0% ± 3.9% and 96.0% ± 2.8%, respectively. The 5-year cumulative risk of relapse was 4.24% ± 2.0%. The treatment was well tolerated. Episodes of neutropenia were of short duration. Patients with B-ALL selected by a combination of presenting features and degree of early response can be successfully treated with a mildly myelosuppressive chemotherapy regimen.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Pedrosa F, Coustan-Smith E, Zhou Y, et al. Reduced-dose intensity therapy for pediatric lymphoblastic leukemia: long-term results of the Recife RELLA05 pilot study. Blood. 2020. PMID: 32027741. doi:10.1182/blood.2019004215

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。